Table 5 Predictors of Recurrent Restenosis within 5 Years after Treatment of In-stent Restenosis in the Matched Population

Age, (per 1 year)

1.03

0.92–1.03

0.343

Male sex

1.40

0.60–3.55

0.460

Body mass index (per 1.0)

0.99

0.89–1.10

0.835

Dyslipidemia

0.83

0.37–1.80

0.640

Diabetes mellitus

1.24

0.51–2.77

0.618

Current smoker

1.58

0.61–3.64

0.324

Chronic kidney disease

1.52

0.65–4.16

0.351

Hemodialysis

1.12

0.18–3.78

0.881

Use of cilostazol

1.30

0.60–2.91

0.505

Involvement of popliteal lesion

1.51

0.59–3.44

0.370

Reference vessel diameter (per 1.0 mm)

0.96

0.40–2.43

0.925

ISR length (per 10.0 mm)

1.04

0.98–1.10

0.172

Tosaka type III (occlusion)

2.10

0.85–4.73

0.102

PACSS grade 4 of native lesions

1.05

0.40–3.58

0.933

Tibial runoff ≤1

1.65

0.72–3.61

0.224

Use of PCB at ISR treatment

0.16

0.06–0.39

< 0.001